Kim Tsuchimoto

International Microcomputer Software, Inc. develops software for productivity, utility, and digital image categories

SpatiaLight, Inc. filed bankruptcy on February 21, 2008. The company previously engaged in the business of manufacturing high-resolution LCoS microdisplays. Its customers are original equipment manufacturers engaged in the business of manufacturing high definition television. The company was founded in 1989 and is headquartered in Novato, CA.

Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million.

The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007.

Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA.

Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016.